PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the safety and clinical efficacy of ABO-incompatible living-donor liver transplantation (LDLT) in children.
UNASSIGNED: The clinical data of 62 children who underwent for the first time living donor liver transplantation in our hospital from April 2019 to July 2020 were retrospectively analyzed. According to the blood type matching of donor and recipient, the patients were divided into 3 groups, ABO-identical (ABO-Id, n=33), ABO-compatible (ABO-C, n=10) and ABO-incompatible (ABO-In, n=19), the median age of recipients in the three groups being 5 months. In the ABO-In group, 4 recipients whose condition was combined with liver failure and 2 recipients who had blood group antibody titers≥1∶32 received preoperative plasma exchange. All ABO-incompatible recipients had preoperative blood group antibody titers<1∶32. All recipients in the three groups underwent piggyback liver transplantation and received immunosuppressive and anticoagulation therapy. Postoperative follow-up was 5 to 20 months, the median being 12 months, measured until December 31, 2020 or until the date of death. Baseline clinical data, postoperative survival, and postoperative complications of recipients in the three groups were analyzed.
UNASSIGNED: There were no significant differences in age, gender, underlying disease, operation history, Child Pugh score, donor age, graft to recipient weight ratio (GR/WR), cold ischemia time, warm ischemia time, duration of surgery, intraoperative blood loss and the use of immunosuppressants among the recipients in the three groups (all P>0.05). There was one death in the perioperative period and two deaths in the postoperative period in the ABO-Id group. There was one death in the postoperative period in the ABO-C group. There was one death in the perioperative period and one death in the postoperative period in the ABO-In group. There was no significant difference in the overall cumulative survival rate among the three groups ( P>0.05). There were no significant differences in the incidence of postoperative infection, acute rejection, biliary anastomotic stenosis and vascular complications among the three groups ( P>0.05).
UNASSIGNED: ABO-In LDLT is an effective and safe treatment option that can effectively expand the pool of live donors for liver transplantation and save the life of children with end-stage liver disease.
UNASSIGNED: The clinical data of 62 children who underwent for the first time living donor liver transplantation in our hospital from April 2019 to July 2020 were retrospectively analyzed. According to the blood type matching of donor and recipient, the patients were divided into 3 groups, ABO-identical (ABO-Id, n=33), ABO-compatible (ABO-C, n=10) and ABO-incompatible (ABO-In, n=19), the median age of recipients in the three groups being 5 months. In the ABO-In group, 4 recipients whose condition was combined with liver failure and 2 recipients who had blood group antibody titers≥1∶32 received preoperative plasma exchange. All ABO-incompatible recipients had preoperative blood group antibody titers<1∶32. All recipients in the three groups underwent piggyback liver transplantation and received immunosuppressive and anticoagulation therapy. Postoperative follow-up was 5 to 20 months, the median being 12 months, measured until December 31, 2020 or until the date of death. Baseline clinical data, postoperative survival, and postoperative complications of recipients in the three groups were analyzed.
UNASSIGNED: There were no significant differences in age, gender, underlying disease, operation history, Child Pugh score, donor age, graft to recipient weight ratio (GR/WR), cold ischemia time, warm ischemia time, duration of surgery, intraoperative blood loss and the use of immunosuppressants among the recipients in the three groups (all P>0.05). There was one death in the perioperative period and two deaths in the postoperative period in the ABO-Id group. There was one death in the postoperative period in the ABO-C group. There was one death in the perioperative period and one death in the postoperative period in the ABO-In group. There was no significant difference in the overall cumulative survival rate among the three groups ( P>0.05). There were no significant differences in the incidence of postoperative infection, acute rejection, biliary anastomotic stenosis and vascular complications among the three groups ( P>0.05).
UNASSIGNED: ABO-In LDLT is an effective and safe treatment option that can effectively expand the pool of live donors for liver transplantation and save the life of children with end-stage liver disease.
摘要：
UASSIGNED：评估儿童ABO不相容活体肝移植（LDLT）的安全性和临床疗效。
UNASSIGNED：回顾性分析2019年4月至2020年7月在我院首次进行活体肝移植的62例患儿的临床资料。根据供者和受者的血型匹配，将患者分为3组，ABO-相同(ABO-Id,n=33),ABO兼容(ABO-C,n=10)和ABO不相容(ABO-In，n=19),三组受者的中位年龄为5个月.在ABO-In组中,4例合并肝功能衰竭的受者和2例血型抗体滴度≥1∶32的受者接受术前血浆置换。所有ABO不相容的受者术前血型抗体滴度均<1∶32。3组受者均行背负式肝移植，并接受免疫抑制和抗凝治疗。术后随访5～20个月,中位数是12个月，测量到2020年12月31日或死亡日期。基线临床数据，术后生存率,并对3组患者术后并发症进行分析。
未经评估：年龄没有显著差异，性别,潜在的疾病，操作历史记录,ChildPugh得分,供体年龄,移植物与受体的重量比（GR/WR），冷缺血时间，热缺血时间，手术持续时间,3组受者术中失血量和免疫抑制剂使用情况(均P>0.05)。ABO-Id组围手术期死亡1例,术后死亡2例。ABO-C组术后有1例死亡。ABO-In组围手术期1例死亡，术后1例死亡。三组总累积生存率比较差异无统计学意义(P>0.05)。术后感染发生率差异无统计学意义,急性排斥反应,3组胆道吻合口狭窄及血管并发症比较(P>0.05)。
UNASSIGNED：ABO-InLDLT是一种有效且安全的治疗选择，可有效扩大肝移植的活体供体库，并挽救终末期肝病患儿的生命。
UNASSIGNED：回顾性分析2019年4月至2020年7月在我院首次进行活体肝移植的62例患儿的临床资料。根据供者和受者的血型匹配，将患者分为3组，ABO-相同(ABO-Id,n=33),ABO兼容(ABO-C,n=10)和ABO不相容(ABO-In，n=19),三组受者的中位年龄为5个月.在ABO-In组中,4例合并肝功能衰竭的受者和2例血型抗体滴度≥1∶32的受者接受术前血浆置换。所有ABO不相容的受者术前血型抗体滴度均<1∶32。3组受者均行背负式肝移植，并接受免疫抑制和抗凝治疗。术后随访5～20个月,中位数是12个月，测量到2020年12月31日或死亡日期。基线临床数据，术后生存率,并对3组患者术后并发症进行分析。
未经评估：年龄没有显著差异，性别,潜在的疾病，操作历史记录,ChildPugh得分,供体年龄,移植物与受体的重量比（GR/WR），冷缺血时间，热缺血时间，手术持续时间,3组受者术中失血量和免疫抑制剂使用情况(均P>0.05)。ABO-Id组围手术期死亡1例,术后死亡2例。ABO-C组术后有1例死亡。ABO-In组围手术期1例死亡，术后1例死亡。三组总累积生存率比较差异无统计学意义(P>0.05)。术后感染发生率差异无统计学意义,急性排斥反应,3组胆道吻合口狭窄及血管并发症比较(P>0.05)。
UNASSIGNED：ABO-InLDLT是一种有效且安全的治疗选择，可有效扩大肝移植的活体供体库，并挽救终末期肝病患儿的生命。
